---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-135935"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:47:47.750796+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q1 2023 net loss $21.7M; cash $646.6M; DDC IND on track for year-end

## Summary
- Net loss of $21.7M ($0.10 per share) vs $21.3M ($0.10) in Q1 2022.
- Cash, cash equivalents and marketable securities of $646.6M as of March 31, 2023.
- R&D expenses decreased to $18.8M from $20.7M, primarily due to headcount reduction and NUV-422 program termination.
- Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy study both enrolling.
- IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023.

## SEC filing metadata
- accession: 0001193125-23-135935
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/0001193125-23-135935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/d301084d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-135935
- JSON: https://secwatch.observer/filing/0001193125-23-135935.json
- Plain text: https://secwatch.observer/filing/0001193125-23-135935.txt

## Key facts
- Earnings Releases
  Nuvation Bio Inc. reported the first quarter ended March 31, 2023 results: net income $21.7 million, EPS $(0.10) per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $21.7 million
  - EPS: $(0.10) per share
  - Result: reported results
  source text: For the three months ended March 31, 2023, Nuvation Bio reported a net loss of $21.7 million, or $(0.10) per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/0001193125-23-135935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.